Innovative Pharmaceutical Biotech (HKEX: 00399) Plans to Acquire Full Ownership of Conflux to Enter the Blockchain Sector
Conflux co-founders are executive directors of the listed company.
Acquisition Plan:
Innovative Pharmaceutical Biotech Limited (IPB) has signed a Memorandum of Understanding (MOU) to acquire 100% equity of a target company.
This acquisition is conditional upon the target company first acquiring all blockchain-related assets of Conflux.
Payment Terms:
The purchase consideration may be paid in cash, company shares, or convertible bonds.
The exact amount has not yet been determined.
Exclusivity Clause:
The MOU is valid for 12 months.
During this period, the seller cannot negotiate with any third party regarding the target company’s shares.
